Hemostemix Inc.
HMTXF
$0.05
$0.00-4.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.67% | -62.79% | -78.74% | 391.03% | 9.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.07% | -35.63% | 128.95% | 536.39% | 10.34% |
| Operating Income | -22.07% | 35.63% | -128.95% | -536.39% | -10.34% |
| Income Before Tax | -169.39% | 36.53% | -101.42% | -56.72% | 56.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -169.39% | 36.53% | -101.42% | -56.72% | 56.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -169.39% | 36.53% | -101.42% | -56.72% | 56.44% |
| EBIT | -22.07% | 35.63% | -128.95% | -536.39% | -10.34% |
| EBITDA | -22.12% | 35.63% | -128.93% | -536.39% | -10.30% |
| EPS Basic | -100.00% | 62.77% | -8.86% | 3.85% | 75.00% |
| Normalized Basic EPS | 17.65% | 57.63% | -32.65% | -170.59% | 37.04% |
| EPS Diluted | -100.00% | 62.77% | -8.86% | 3.85% | 75.00% |
| Normalized Diluted EPS | 17.65% | 57.63% | -32.65% | -170.59% | 37.04% |
| Average Basic Shares Outstanding | 39.95% | 71.93% | 83.23% | 68.12% | 68.12% |
| Average Diluted Shares Outstanding | 39.95% | 71.93% | 83.23% | 68.12% | 68.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |